Biocryst looks to raise the profile of its factor D inhibitor
The relatively low-key asset might at least partly be responsible for Biocryst shares more than doubling since the start of December.
Asco-GU – Clear blue water between Keytruda and kidney cancer rivals
Merck & Co/Eisai’s Clear study results look better than Bristol/Exelixis’s Checkmate-9ER, but the big loser could be Pfizer.
Asco-GU – confirmatory Padcev trial throws a curveball
Subgroup analysis of a confirmatory US study in bladder cancer suggests no benefit in female patients.
Novartis’s canakinumab cancer test approaches
Will it be a new class of cancer drug or another failure for Novartis’s IL-1 inhibitor?
World Symposium – Orchard leads the crop of Hurler syndrome hopefuls
Promising early data with the group’s gene therapy put it ahead of Regenxbio for now.
Asco-GU – Bristol in pole position with Opdivo’s adjuvant use
Bladder cancer is the fourth tumour type to give Opdivo a phase III adjuvant win, and the extent of the survival benefit is impressive.
World Lung 2020 – amivantamab puts more data behind the hype
But how will the complex J&J bispecific antibody fare in a market where oral small molecules are the norm?
World Lung 2020 – Yervoy’s front-line impotence laid bare
Full data show just how big a bust Keynote-598 is, though Bristol is unlikely to abandon hope.
World Lung 2020 – no advance on Amgen’s “consistent” Kras promise
But the unveiling of sotorasib’s registrational dataset shows that bulls should be cautious of Mirati's numerical advantage.
